Gilead Sciences Inc (GILD)

[Tha Part Time Er]

After getting positive data for its antiviral remdesivir in patients with COVID-19 and the Food and Drug Administration's authorization to use the drug last week, Gilead Sciences (NASDAQ:GILD) is turning its sights on making sure the drug is available globally.

On Tuesday, the biotech announced plans to increase the manufacturing of remdesivir, a drug that is quite hard to make and requires scarce raw materials that need to be produced separately.

Gilead is in discussions with other manufacturers that may be able to produce the drug for Europe, Asia, and the developing world through at least 2022. The company is also negotiating long-term voluntary licenses with multiple generic-drug makers in India and Pakistan, which would produce remdesivir for developing countries.

On the patent front, the company is working the Medicines Patent Pool, a United Nations-backed public health organization that acts as an intermediary between branded-drug companies and generic-drug companies to provide drugs to developing countries. Gilead has previously worked with Medicines Patent Pool to bring its HIV drugs to developing countries.

To get the drugs to the countries in need, Gilead is in discussions with UNICEF to hopefully use its distribution networks in low- and middle-income countries.